Back to Single Peptide Protocols
Single PeptideMetabolic & Weight Loss5 mg vialOnce dailySubcutaneousLipolytic

AOD-9604 (5 mg Vial) Dosage Protocol

AOD-9604 dosage protocol for the 5 mg vial. Modified hGH fragment (176–191) studied for selective lipolysis without affecting blood glucose or IGF-1.

Vial Size
5 mg
Route
Subcutaneous
Frequency
Once daily
Dose Range
250–500 mcg/day

Dosage Schedule

PeriodDose
Weeks 1–4250 mcg/day
Weeks 5+ (maintenance)500 mcg/day

Route: Subcutaneous · Frequency: Once daily · Cycle: 4–12 weeks

How It Works

AOD-9604 mimics the lipolytic region of hGH by activating β3-adrenergic receptors in adipose tissue, stimulating fat breakdown without binding IGF-1 receptors. This produces fat loss without the insulin resistance or growth-promoting effects of full hGH.

Potential Benefits

  • •Selective lipolysis stimulation.
  • •No effect on blood glucose or IGF-1.
  • •Potential cartilage repair properties in preclinical models.
  • •TGA-approved food ingredient (Australia).

Side Effects & Risks

  • •Injection-site reactions.
  • •Mild headache.
  • •Generally well-tolerated in Phase 2 trials.

Important Notes

  • Investigational compound — not FDA-approved.
  • Best administered on an empty stomach in the morning.

Storage Instructions

  • Lyophilized: −20 °C (−4 °F).
  • Once mixed: 2–8 °C; use within 14–21 days.

References

  1. [1]Ng FM et al. Metabolic studies of a growth hormone-releasing peptide. J Mol Endocrinol 1990.View Source

Research & Educational Use Only: This protocol is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making any decisions related to peptides or any other compounds.